Caris Life (CAI) director granted 1,600 shares for 2026 board fees

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

POSTE GEORGE reported acquisition or exercise transactions in this Form 4 filing.

Caris Life Sciences director George Poste reported routine equity compensation and a prior ownership reclassification. He received 1,600 shares of common stock as a grant in lieu of cash 2026 board retainer fees, based on a ten-day average price of $15.62 per share. After this award, he holds 17,729 shares directly. A previous transfer of 204,108 shares from direct ownership into a family trust contributed to an indirect total of 511,702 shares, and did not change his overall beneficial ownership.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider POSTE GEORGE

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,600	$15.62	$25K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 17,729 shares (Direct, null); Common Stock — 511,702 shares (Indirect, By Family Trust)

Footnotes (1)

Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026. Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities.

Key Figures

Stock grant: 1,600 shares Reference price: $15.62 per share Direct holdings after grant: 17,729 shares +2 more

5 metrics

Stock grant 1,600 shares Common stock issued in lieu of 2026 board cash retainer

Reference price $15.62 per share Ten-day average volume-weighted average price through May 29, 2026

Direct holdings after grant 17,729 shares Common stock directly owned after the 1,600-share award

Indirect holdings via family trust 511,702 shares Common stock held indirectly through a family trust

Shares transferred to trust 204,108 shares Previously moved from direct ownership to a family trust

Key Terms

in lieu of cash compensation, volume weighted average price, beneficial ownership, family trust

4 terms

in lieu of cash compensation financial

"Shares issued in lieu of cash compensation for 2026 board retainer fees."

volume weighted average price financial

"ten trading day average of the daily volume weighted average price per share"

The volume weighted average price (VWAP) is a way to measure the average price of a security, such as a stock, over a specific period, taking into account how many units were traded at each price. It’s similar to calculating the average cost of items bought when some are more frequently purchased than others. Investors use VWAP to assess whether a security is being bought or sold at a fair price during trading.

beneficial ownership financial

"The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

family trust financial

"transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/02/2026 - 05:44 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POSTE GEORGE

(Last)

(First)

(Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING

TEXAS

75039

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/29/2026		A⁽¹⁾		1,600	A	$15.62	17,729⁽²⁾	D
Common Stock								511,702⁽²⁾	I	By Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026.

2. Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities.

Remarks:

	/s/ J. Russel Denton, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Caris Life Sciences (CAI) report for George Poste?

Caris Life Sciences reported a routine equity grant to director George Poste. He received 1,600 common shares as compensation, rather than cash, for his 2026 board retainer fees, and his overall beneficial ownership remained unchanged after a prior transfer to a family trust.

How many Caris Life Sciences (CAI) shares did George Poste receive in this Form 4?

George Poste received 1,600 shares of Caris Life Sciences common stock. These shares were issued as a grant in lieu of cash board retainer fees, with the number of shares determined using a ten-day average volume-weighted average price through May 29, 2026.

What price was used to calculate George Poste’s Caris Life Sciences (CAI) stock grant?

The stock grant was based on a reference price of $15.62 per share. The company determined the 1,600-share award by dividing the cash retainer earned by the ten trading day average volume-weighted average price per share through May 29, 2026.

What are George Poste’s direct and indirect Caris Life Sciences (CAI) holdings after this filing?

After the reported transactions, George Poste directly holds 17,729 shares. He also indirectly holds 511,702 shares through a family trust, reflecting a prior transfer of 204,108 shares that did not change his aggregate beneficial ownership of Caris Life Sciences stock.

Did the family trust transfer change George Poste’s total Caris Life Sciences (CAI) ownership?

No, the transfer to the family trust did not change his total beneficial ownership. A prior movement of 204,108 shares from direct ownership into a family trust only shifted how the shares are held, with the position now reflected as indirect ownership.

Why did Caris Life Sciences (CAI) issue shares to George Poste instead of cash?

The company issued shares in lieu of cash for 2026 board retainer fees. George Poste’s compensation was delivered as 1,600 common shares, calculated by dividing his cash retainer amount by the ten-day average volume-weighted average share price through May 29, 2026.